Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Overview

This multi-center center phase I/II study to establish the lowest possible recommended phase 2 dose (RP2D) of corticosteroids in conjunction with ruxolitinib and uhCG/EGF (a novel combination) for high-risk aGVHD.

This is a single arm study designed to determine the lowest dose of corticosteroids required (toxicity endpoint) without impairing GVHD complete response or partial response (CR/PR) at day 28 when given in conjunction with uhCG/EGF and ruxolitinib.

After completion of the corticosteroid dose finding, the final dose will be carried forward into a two-stage phase II extension trial to confirm safety and make a preliminary determination of efficacy of this novel drug combination for high-risk aGVHD.

Eligibility

Inclusion Criteria:

        HCT recipients over 12 years of age within the first 7 days of initial treatment of
        high-risk aGVHD, defined as:
          -  Newly diagnosed Minnesota high-risk aGVHD -OR-
          -  Newly diagnosed Minnesota standard risk aGVHD with plasma amphiregulin ≥ 33 pg/ml
             tested at the UMN Cytokine Reference Lab. For amphiregulin lab ordering information,
             see Fairview Lab Guide:
             http://labguide.fairview.org/showtest.asp?testid=6766&format=long -OR-
          -  Newly diagnosed Minnesota standard risk aGVHD Ann Arbor 3 biomarkers tested by
             Viracor. For ordering information, see:
             https://www.viracor-eurofins.com/test-menu/403572p-agvhd-symptomatic- onset-algorithm/
               -  Renal: Serum creatinine ≤2.5x upper limit of normal (ULN)
               -  Cardiac: Left ventricular ejection fraction (LVEF) ≥ 35%
               -  Voluntary written consent (adult or parent/guardian with minor assent for 12
                  through 17-year-olds).
        Exclusion Criteria:
          -  Progressive malignancy
          -  Uncontrolled bacterial, fungal, parasitic, or viral infection at initiation of
             protocol treatment
          -  Unwilling or unable to stop supplemental sex hormone therapy (estrogen, progesterone,
             and/or testosterone preparations)
          -  Unwilling or unable to stop GnRH antagonists, aromatase inhibitors, or anti-androgens
          -  History of a hormone responsive malignancy
          -  Current thromboembolic disease requiring full-dose anticoagulation - patients
             receiving pharmacologic prophylaxis for thromboembolic disease will be eligible
          -  Active or recent (within prior 3 months) thrombus, irrespective of anticoagulation
             status
          -  Pregnancy
          -  Women or men of childbearing potential unwilling to take adequate precautions to avoid
             unintended pregnancy from the start of protocol treatment through 30 days after the
             last treatment